[go: up one dir, main page]

EP0542753A1 - Epitopes de la region pre-s de l'antigene de surface du virus de l'hepatite b - Google Patents

Epitopes de la region pre-s de l'antigene de surface du virus de l'hepatite b

Info

Publication number
EP0542753A1
EP0542753A1 EP19910910584 EP91910584A EP0542753A1 EP 0542753 A1 EP0542753 A1 EP 0542753A1 EP 19910910584 EP19910910584 EP 19910910584 EP 91910584 A EP91910584 A EP 91910584A EP 0542753 A1 EP0542753 A1 EP 0542753A1
Authority
EP
European Patent Office
Prior art keywords
hbsag
polypeptide
amino acid
acid residue
cell epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910910584
Other languages
German (de)
English (en)
Other versions
EP0542753A4 (en
Inventor
David R. Milich
George B. Thornton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Clinic and Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic and Research Foundation filed Critical Scripps Clinic and Research Foundation
Publication of EP0542753A1 publication Critical patent/EP0542753A1/fr
Publication of EP0542753A4 publication Critical patent/EP0542753A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • polypeptides referred to as p39, p33 and p25 are polypeptides referred to as p39, p33 and p25,
  • the antigens tested for induction of T cell proliferation included pre-S(2)-containing
  • substitutions have been made, usually not more than about 20% and more frequently not more than 10% of the amino acid residues differ.
  • sequences which "substantially correspond" to a specified sequence are those having not more than 10% deletions, insertions or substitutions.
  • additional residues may be added at either terminus.
  • the additional residues may correspond to contiguous residues in the linear sequence of HBsAg as described previously, or may be repeats of the sequence or amino acid residues that are unrelated to HBsAg.
  • vaccine in its various grammatical forms is used herein to describe a type of inoculum containing one or more polypeptide of this invention as an active ingredient that is used to induce active immunity in a host mammal against HBV. Since active immunity involves the production of antibodies, a vaccine or inoculum may thus contain identical
  • a plurality of T cell epitopes of each subtype are administered.
  • HBsAg sandwich enzyme-linked immunosorbent assay
  • Synthetic polypeptides having a sequence corresponding to p133-174/ad or p131-174/ad were prepared and injected into mice as described above.
  • the induced antibody was analyzed by ELISA as
  • H-2 haplotypes H-2 f,s
  • H-2 t4 H-2 haplotypes
  • a nonresponding haplotype following HBsAg/p39 immunization has not yet been identified amongst the following H-2 haplotypes studied to date: q, d, s, k, b, p, f, t4.
  • FIG. 5 demonstrates that T cell recognition in a variety of strains is focused on the C-terminal half of the pre-S (2) region.
  • HBsAg/P33d-primed T cells from a number of strains were cultured with full length (P33) or N-terminally truncated (P28) HBsAg particles. Because the truncated version elicited significant T cell proliferation in all strains immunized with HBsAg/P33, it appears that the N- terminal residues (120-139) do not play a significant role in T cell recognition.
  • B10 HBsAg/P33-primed T cells react efficiently with HBsAg/P28 (the truncated sequence), p141-160 and p146-165, consistent with the dominant T cell site, p149-157, which was also defined with synthetic peptides p133-174 and p148-174 as immunogens.
  • B10.M HBsAg/P33-primed T cells react efficiently with HBsAg/P28, p151-170, and p156-174, consistent with the dominant site p156-167, which was also defined with synthetic peptides p133- 174 and p148-174 as the immunogens (Figure 11B).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polypeptides correspondant dans une séquence de restes d'acide aminé à des épitopes de lymphocytes T natifs dans la région pré-S(2) de l'antigène de surface du virus de l'hépatite B (HBsAg). L'invention concerne également un procédé de modération du manque de faculté de réponse au HBsAg consistant à introduire des épitopes de lymphocyte T des sous-types d et y.
EP19910910584 1990-05-11 1991-05-10 Epitopes of the pre-s region of hepatitis b virus surface antigen Withdrawn EP0542753A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52266390A 1990-05-11 1990-05-11
US522663 1990-05-11

Publications (2)

Publication Number Publication Date
EP0542753A1 true EP0542753A1 (fr) 1993-05-26
EP0542753A4 EP0542753A4 (en) 1993-09-08

Family

ID=24081802

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910910584 Withdrawn EP0542753A4 (en) 1990-05-11 1991-05-10 Epitopes of the pre-s region of hepatitis b virus surface antigen

Country Status (5)

Country Link
EP (1) EP0542753A4 (fr)
AU (1) AU7909391A (fr)
IE (1) IE911614A1 (fr)
PT (1) PT97632A (fr)
WO (1) WO1991017768A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1998012332A1 (fr) 1996-09-17 1998-03-26 Chiron Corporation Compositions et procedes de traitement de maladies intracellulaires
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
US20220411475A1 (en) * 2019-11-18 2022-12-29 Vlp Biotech, Inc. Hybrid virus-like particles and use thereof as a therapeutic hepatitis b vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007896A1 (fr) * 1986-06-20 1987-12-30 Scripps Clinic And Research Foundation Epitopes des cellules t et b de la region pre-s de l'antigene de surface du virus de l'hepatite b

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4683136A (en) * 1985-03-06 1987-07-28 Scripps Clinic And Research Foundation Proteinaceous antigens with conformation-independent and conformation-dependent determinants
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007896A1 (fr) * 1986-06-20 1987-12-30 Scripps Clinic And Research Foundation Epitopes des cellules t et b de la region pre-s de l'antigene de surface du virus de l'hepatite b

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANN. INST. PASTEUR VIROL. vol. 139, no. 1, 1988, pages 13 - 38 A. NEURATH ET AL. 'Delineation of contiguous determinants essential for biological functions of the pre-s sequence of hepatitis B virus envelope protein' *
PROC. NATL ACAD. SCI. USA vol. 85, 1988, pages 1610 - 1614 D. MILICH ET AL. 'Hepatitis B synthetic immunogen composed of nucleocapsid T-cell sites and an envelope B cell epitope' *
PROC. NATL. ACAD. SCI. USA vol. 86, 1989, pages 9084 - 9088 J. TAM 'Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines' *
See also references of WO9117768A1 *

Also Published As

Publication number Publication date
IE911614A1 (en) 1992-09-23
WO1991017768A1 (fr) 1991-11-28
EP0542753A4 (en) 1993-09-08
AU7909391A (en) 1991-12-10
PT97632A (pt) 1992-03-31

Similar Documents

Publication Publication Date Title
CA1329766C (fr) Epitopes d'une proteine de la capside nucleique du virus de l'hepatite b stimulant les lymphocytes t
US5143726A (en) T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) T cell epitopes of the hepatitis B virus nucleocapsid protein
US4599230A (en) Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
Dreesman et al. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides
EP0155146B1 (fr) Vaccin synthétique contre le virus de l'hepatite B incluant des déterminants des cellules T et des cellules B
JPS62502704A (ja) 立体配座−独立並びに立体配座依存決定基を有するタンパク抗原
Murray et al. Protective immunisation against hepatitis B with an internal antigen of the virus
AU617292B2 (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
AU628156B2 (en) Monoclonal antibodies to pres2 and pres1 polypeptides of the hepatitis b viral envelope
JP3000569B2 (ja) Ｂ型肝炎ウイルスコア抗原のアミノ酸残基配列
JPH0925300A (ja) Ｈｔｌｖ−ｉｉｉ／ｌａｖウイルス関連ペプチドに対する抗体
AU646039B2 (en) Monoclonal antibodies to Pres2 and Pres1 polypeptides of the hepatitis B viral envelope
EP0542753A1 (fr) Epitopes de la region pre-s de l'antigene de surface du virus de l'hepatite b
US4778784A (en) Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus
EP0426314B1 (fr) Peptides liées au HIV
Mishra et al. Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen
Kennedy et al. HEPATITIS B SURFACE ANTIGEN POLYPEPTIDE AND SYNTHETIC PEPTIDE VACCINES
Dreesman et al. Hepatitis B surface antigen Polypeptide and synthetic peptide vaccines
JPH045300A (ja) Ｂ型肝炎ワクチンおよびＨＢｓ抗原特異抗体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THORNTON, GEORGE B.

Inventor name: MILICH, DAVID R.

A4 Supplementary search report drawn up and despatched

Effective date: 19930726

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19931010